| Added by | tchardes |
|---|---|
| Group name | EquipeELC |
| Item Type | Journal Article |
| Title | [2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France] |
| Creator | Franchet et al. |
| Author | Camille Franchet |
| Author | Lounes Djerroudi |
| Author | Aurélie Maran-Gonzalez |
| Author | Olivia Abramovici |
| Author | Martine Antoine |
| Author | Anca Berghian |
| Author | Cécile Blanc-Fournier |
| Author | Eva Brabencova |
| Author | Emmanuelle Charafe-Jauffret |
| Author | Marie-Pierre Chenard |
| Author | Marie-Mélanie Dauplat |
| Author | Paul Delrée |
| Author | Clémence Fleury |
| Author | Jean-Pierre Ghnassia |
| Author | Juliette Haudebourg |
| Author | Agnès Leroux |
| Author | Marie-Christine Mathieu |
| Author | Patrick Michenet |
| Author | Frédérique Penault-Llorca |
| Author | Bruno Poulet |
| Author | Yves Marie Robin |
| Author | Pascal Roger |
| Author | Elisabeth Russ |
| Author | Lucie Tixier |
| Author | Isabelle Treilleux |
| Author | Alexander Valent |
| Author | Véronique Verriele |
| Author | Anne Vincent-Salomon |
| Author | Laurent Arnould |
| Author | Magali Lacroix-Triki |
| Abstract | The last international guidelines on HER2 determination in breast cancer have been updated in 2018 by the American Society of Clinical Oncology and College of American Pathologists, on the basis of a twenty-year practice and results of numerous clinical trials. Moreover, the emerging HER2-low concept for 1+ and 2+ non amplified breast cancers lead to refine French practices for HER2 status assessment. The GEFPICS group, composed of expert pathologists, herein presents the latest French recommendations for HER2 status evaluation in breast cancer, taking into account the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, HER2 status assessment remains one of the most important biomarkers in breast cancer and its quality guaranties the optimal patients' care. French pathologists' commitment in theranostic biomarker quality is more than ever required to provide the most efficient cares in oncology. |
| Publication | Annales De Pathologie |
| Pages | S0242-6498(21)00191-7 |
| Date | 2021-08-12 |
| Journal Abbr | Ann Pathol |
| Language | fre |
| DOI | 10.1016/j.annpat.2021.07.014 |
| ISSN | 0242-6498 |
| Library Catalog | PubMed |
| Extra | PMID: 34393014 |
| Tags | Cancer du sein, clinic, ERBB2, Guidelines, HER2, Hybridation in situ, Immunohistochemistry, Immunohistochimie, Recommandations |
| Date Added | 2021/10/01 - 17:24:06 |
| Date Modified | 2021/10/01 - 17:27:46 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
